

d his

(FILE 'HOME' ENTERED AT 16:18:55 ON 26 NOV 2003)

FILE 'MEDLINE' ENTERED AT 16:19:06 ON 26 NOV 2003

L1	14173 S PAPILOMAVIRUS
L2	846 S HPV (W) 18
L3	2046 S "L1" AND "L2"
L4	15 S L2 AND L3 E JANSEN K U/AU
L5	24 S E3
L6	11 S E10
L7	16 S L5 AND L1
L8	9 S L6 AND L1
L9	0 S L4 AND L8
L10	0 S L4 AND L7
L11	2037 S VIRUS LIKE PARTICLES
L12	15 S L7 AND L11
L13	2 S L8 AND L11

d 112 12 all

L12 ANSWER 12 OF 15 MEDLINE on STN
AN 96177328 MEDLINE
DN 96177328 PubMed ID: 8601783
TI Sequence conservation within the major capsid protein of human
papillomavirus (HPV) type 18 and formation of HPV-18 **virus**
-like particles in *Saccharomyces cerevisiae*.
AU Hofmann K J; Neeper M P; Markus H Z; Brown D R; Muller M; Jansen K
U
CS Department of Virus and Cell Biology, Merck Research Laboratories, West
Point, Pennsylvania 19486, USA.
SO JOURNAL OF GENERAL VIROLOGY, (1996 Mar) 77 (Pt 3) 465-8.
Journal code: 0077340. ISSN: 0022-1317.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
OS GENBANK-X05015
EM 199605
ED Entered STN: 19960517
Last Updated on STN: 19970203
Entered Medline: 19960503
AB The major capsid protein L1 of human papillomaviruses (HPVs) has been
identified as a promising candidate antigen for a prophylactic HPV
vaccine. Since amino acid sequence heterogeneity has been demonstrated
for the L1 genes within individual HPV types, nucleotide sequences of L1
were determined from six HPV-18 clinical isolates and the cervical
carcinoma cell line SW756 and compared to the published HPV-18 prototype
sequence. The sequences were almost identical between the clinical
isolates and SW756 but differed markedly from the published prototype
sequence. Resequencing the prototype HPV-18 revealed that these
differences were due to sequencing artifacts of the prototype HPV-18
sequence archived in GenBank. Thus, the HPV-18 L1 genes seem to display a
very high level of sequence conservation. The HPV-18 L1 gene derived from
SW756 was expressed in *Saccharomyces cerevisiae* and self-assembly of the
L1 protein into **virus-like particles** was
demonstrated.
CT Check Tags: Human

d 112 1-15 ti

- L12 ANSWER 1 OF 15 MEDLINE on STN
TI Hybrid **papillomavirus** L1 molecules assemble into **virus-like particles** that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
- L12 ANSWER 2 OF 15 MEDLINE on STN
TI A novel human **papillomavirus** type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1.
- L12 ANSWER 3 OF 15 MEDLINE on STN
TI Neutralization of human **papillomavirus** type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 **virus-like particles**: correlation with competitive radioimmunoassay titer.
- L12 ANSWER 4 OF 15 MEDLINE on STN
TI Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human **papillomavirus virus-like particles**.
- L12 ANSWER 5 OF 15 MEDLINE on STN
TI Neutralization of human **papillomavirus** (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies.
- L12 ANSWER 6 OF 15 MEDLINE on STN
TI HPV11 mutant **virus-like particles** elicit immune responses that neutralize virus and delineate a novel neutralizing domain.
- L12 ANSWER 7 OF 15 MEDLINE on STN
TI Purification of **virus-like particles** of recombinant human **papillomavirus** type 11 major capsid protein L1 from *Saccharomyces cerevisiae*.
- L12 ANSWER 8 OF 15 MEDLINE on STN
TI The L1 major capsid protein of human **papillomavirus** type 11 recombinant **virus-like particles** interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes.
- L12 ANSWER 9 OF 15 MEDLINE on STN
TI Human **papillomavirus** type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
- L12 ANSWER 10 OF 15 MEDLINE on STN
TI Human **papillomavirus** type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 **virus-like particles** expressed in yeast.
- L12 ANSWER 11 OF 15 MEDLINE on STN
TI Expression of the major capsid protein of human **papillomavirus** type 11 in *Saccharomyces cerevisiae*.
- L12 ANSWER 12 OF 15 MEDLINE on STN
TI Sequence conservation within the major capsid protein of human **papillomavirus** (HPV) type 18 and formation of HPV-18 **virus-like particles** in *Saccharomyces cerevisiae*.
- L12 ANSWER 13 OF 15 MEDLINE on STN

TI Vaccination with yeast-expressed cottontail rabbit **papillomavirus** (CRPV) **virus-like particles** protects rabbits from CRPV-induced papilloma formation.

L12 ANSWER 14 OF 15 MEDLINE on STN

TI Protection against **papillomavirus** with a polynucleotide vaccine.

L12 ANSWER 15 OF 15 MEDLINE on STN

TI Sequence determination of human **papillomavirus** type 6a and assembly of **virus-like particles** in *Saccharomyces cerevisiae*.